Zhejiang NuoDe Pharmaceutical Co., Ltd.

This study aimed to investigate the pharmacokinetic characteristics of mosapride citrate tablets (5 mg) developed and manufactured by Zhejiang Nuode Pharmaceutical Co., Ltd., administered orally in both fasting and postprandial doses. Mosapride citrate tablets (Gasqing®, 5 mg), manufactured by Sumitomo Pharma Co., Ltd. and licensed by Sumitomo Pharma Co., Ltd. Suzuka Plant, were used as a reference formulation. The pharmacokinetic parameters Cmax and AUC0-t of the two formulations were compared to evaluate their bioequivalence in humans.

This study aimed to investigate the pharmacokinetic characteristics of a single oral dose of oseltamivir phosphate granules (0.9 g, calculated as C16H28N2O4) manufactured by Zhejiang Nuode Pharmaceutical Co., Ltd., under fasting and postprandial conditions. Oseltamivir phosphate dry syrup (Tamiflu®, 3% (30 mg/g)) certified by Chugai Pharmaceutical Co., Ltd. was used as the reference formulation. The pharmacokinetic parameters Cmax and AUC0-t of the two formulations were compared to evaluate their bioequivalence in humans.

This study aimed to investigate the pharmacokinetic characteristics of candesartan medoxomil/hydrochlorothiazide tablets (I) (8 mg/12.5 mg) manufactured by Zhejiang Nuode Pharmaceutical Co., Ltd., after a single fasting oral administration to healthy participants. Candesartan medoxomil/hydrochlorothiazide tablets (Blopress®, 8 mg/12.5 mg), licensed by Cheplapharm Arzneimittel GmbH and manufactured by Delpharm Novara S.r.l., were used as a reference formulation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two formulations were compared to evaluate their bioequivalence in humans and to observe their safety in healthy participants.